Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

(2019) Zhiling Yan et al.   Lancet Haematology

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

(2017) Yinmeng Yang et al.   Science Translational Medicine

Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu

(2017) L Zhang et al.   Blood Cancer Journal

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

New Insights into IL-10 Dependent and IL-10 Independent Mechanisms of Regulatory B Cell Immune Suppression

(2016) Achilleas Floudas et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

(2016) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow

(2012) K. Boucher et al.   CLINICAL CANCER RESEARCH

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

(2012) Alice P. Chen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

(2012) N Hosen et al.   LEUKEMIA

Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells

(2011) Aharon Kessel et al.   AUTOIMMUNITY REVIEWS

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH